AMA Backs Nationwide Ban on Flavored Cannabis Vapes

The American Medical Association (AMA), the country’s largest physician group, has adopted policy urging a nationwide ban on flavored cannabis vaping products — a position that would reach every licensed dispensary and hemp shop that stocks them. The organization approved the measure alongside a second cannabis resolution that takes a more measured view of marijuana for older adults, recognizing both its risks and its potential medical uses.

Both cleared the AMA’s House of Delegates, its policy-making body, at the group’s annual meeting in Chicago in June 2026. The AMA doesn’t write law. But its adopted positions carry weight with state regulators, members of Congress, and the state and specialty medical societies that lobby them — which makes the flavored-vape stance the more consequential of the two for cannabis and hemp operators.

What the vape policy targets

The AMA folded the cannabis measure into a broader package aimed at flavored e-cigarettes and youth vaping, including its opposition to a federal decision allowing fruit-flavored nicotine products onto the market. It adopted policy to seek a prohibition on flavored cannabis vaping products sold in licensed dispensaries, at hemp retailers, and at other outlets, and to push for legislative changes supporting a nationwide ban. The reasoning mirrors decades of tobacco-control argument: flavored cartridges mask cannabis’s harsh, earthy taste and, the AMA contends, make the products more appealing to teenagers.

AMA immediate past president Bobby Mukkamala framed the wider anti-vaping push bluntly. “There is no public health justification for flavoring e-cigarette and vape products in ways that make them more attractive to children and teens,” he said.

The scope is what operators should watch. A ban written to cover hemp product retailers as well as state-licensed dispensaries would sweep in the loosely regulated market for hemp-derived THC that has grown up outside state cannabis systems — the vape pens and cartridges sold in smoke shops and convenience stores in states without legal marijuana. Flavored cartridges are a core part of that product line, and their removal would reshape shelves in both channels. That market is already under federal pressure: a national ban on intoxicating hemp products is set to take effect, though House Republicans have pushed amendments to block it.

A more careful line on older adults

The second resolution, “Medical Cannabis Use in Older Adults,” originated with the AMA’s Senior Physicians Section and was adopted as amended. It stakes out a notably more open position than the AMA’s blanket skepticism, acknowledging that the evidence on marijuana in older patients is thin and points in both directions.

The measure flags a higher incidence of dementia among people who use cannabis, but it also notes that the drug may help manage agitation in dementia patients, potentially as an alternative to antipsychotic medications. Rather than settle the question, it directs the AMA to develop educational materials for clinicians and to press for expanded research into both the therapeutic uses and the adverse effects of cannabis in seniors.

That caution tracks a real shift in who is using the drug. Adults 65 and older are among the fastest-growing groups of cannabis users in the United States; use in that age group climbed nearly 46% between 2021 and 2023, according to federal survey data, with 7% reporting use in the past month. Many are reaching for it to manage pain and sleep, a trend MyCannabis has tracked in its reporting on why older adults are turning to cannabis edibles. Geriatricians caution that cannabis can interact with other medications and raise the risk of falls and accidents in that population.

Where the AMA still stands

For all the nuance, the AMA remains an opponent of commercial legalization. Its standing policy describes cannabis as a “dangerous drug and a serious public health concern” and holds that sales for adult use should not be legalized. The group has, however, softened at the edges through its recent resolutions — backing the expungement of past cannabis convictions in states that have legalized the drug, and favoring public-health approaches over incarceration for drug possession.

The pair of resolutions captures that ambivalence. A body that won’t endorse legalization is nonetheless conceding medical value and asking for more study, even as a growing research base links medical cannabis access to measurable effects, including fewer missed workdays in states with medical programs.

What happens next rests with legislators and regulators, not physicians. State lawmakers and cannabis agencies decide what dispensaries and hemp shops may sell, and several are already weighing restrictions on flavors and youth-facing packaging. The AMA’s endorsement hands that effort a prominent medical stamp heading into the next round of state legislative sessions, and it gives regulators political cover to act.